Next weight-loss breakthrough? AstraZeneca tests a daily pill - Elepeglitron:
AstraZeneca’s daily weight-loss pill elecoglipron delivers 11.8% body weight ...
wionews.com/science/next-weight-loss-breakthrough-astrazeneca-tests-a-daily-pill-1780986473092
Story Details
| Last Updated | |
| Total Articles | 1 |
Main Topics
research involving fundamental scientific principles that may apply to a preclinical understanding – to clinical research, which involves studies of people who may be subjects in clinical trials
Similar to This
Previous
Higher sales of the Wegovy pill: Novo Nordisk raises forecast: The introduction of the Wegovy pill secures higher revenues for the Danish pharmaceutical company ...
faz.net/aktuell/wirtschaft/unternehmen/hoehere-verkaeufe-der-wegovy-pille-novo-nordisk-hebt-prognose-an-201650151.html
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly
reuters.com/business/healthcare-pharmaceuticals/next-medicine-deal-after-pfizer-analysts-shares-point-astrazeneca-eli-lilly-2025-10-10/
AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh: AstraZeneca said the "cornerstone" of the commitment would be a new weight management ...
cnbc.com/2025/07/22/astrazeneca-to-invest-50-billion-in-the-us-as-pharma-tariffs-weigh.html
AstraZeneca vows to spend US$50bil on US manufacturing boost: AstraZeneca Plc plans to invest US$50bil in the United States before 2030, becoming the latest ...
thestar.com.my/business/business-news/2025/07/23/astrazenecavows-to-spend-us50bil-on-us-manufacturing-boost
help.medscape.com Oct 11 24
Because screening [for MASLD/MASH] isn’t widespread, patients often aren’t diagnosed until they experience complications of cirrhosis ... Show more
help.medscape.com Sep 27 24
Check out the new simulation of 2 cases:
• Treatment options for an overweight 58-yr old with type 2 diabetes & a FIB-4 score of 2 ... Show more
Clinical Advances in MASH: A Guide to Managing Metabolic-Dysfunction Associated Steatohepatitis
medscape.org/sites/advances/mash-advances
JAK Inhibitors for Patients With Chronic Inflammatory Conditions: Assessing the Benefits and Risks in Clinical Practice
medscape.org/viewarticle/997681
Next